{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:36:23Z","timestamp":1791081383313,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Up to 30% of patients with hemophilia A given therapeutic factor VIII (fVIII) can make inhibitory antibodies, the majority of which are reactive with its C2 and A2 domains. We have previously demonstrated that antigen-specific tolerance to several antigens can be induced by lipopolysaccharide (LPS)-activated B-cell blasts transduced with immunoglobulin (IgG)-antigen fusion constructs. To apply this system to hemophilia A inhibitor formation, we created retroviral vectors expressing fVIII amino acids S2173-Y2332 (C2 domain) and S373-R740 (A2 domain) in frame with an IgG heavy chain backbone. These vectors were transduced into B-cell blasts to induce tolerance in both naive and fVIII-primed hemophilic (E16 fVIII-\/-) mice. Thus, treatment of E16 fVIII-\/- mice with B cells expressing fVIII C2 and A2 domains led to tolerance in terms of specific humoral response (including inhibitory antibody titers) and cellular responses to fVIII and its C2 or A2 domains. Moreover, a significant reduction in immune responses to fVIII could be achieved in immunized hemophilic mice with existing anti-fVIII titers. This hyporesponsive state persisted for at least 2 months and withstood additional challenge with fVIII. Further experiments, in which mice were treated with a depleting monoclonal anti-CD25, suggested that a regulatory T cell may be required for the tolerogenic effect of transduced B cells. These findings demonstrate that B-cell presentation of fVIII domains on an Ig backbone specifically prevents or decreases existing antibodies in hemophilia A mice. (Blood. 2005;105:4865-4870)<\/jats:p>","DOI":"10.1182\/blood-2004-11-4274","type":"journal-article","created":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T22:28:45Z","timestamp":1110925725000},"page":"4865-4870","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":132,"title":["Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins"],"prefix":"10.1182","volume":"105","author":[{"given":"Tie Chi","family":"Lei","sequence":"first","affiliation":[{"name":"From the Departments of Surgery and of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery and of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223504623000_REF1","doi-asserted-by":"crossref","unstructured":"Jacquemin MG, Saint-Remy JM. FVIII alloantibodies in hemophilia. Curr Opin Hematol.2004;11: 146-150.","DOI":"10.1097\/01.moh.0000130312.87668.bf"},{"key":"2020021223504623000_REF2","doi-asserted-by":"crossref","unstructured":"Villard S, Lacroix-Desmazes S, Kieber-Emmons T, et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-fVIII inhibitor. Blood.2003;102: 949-952.","DOI":"10.1182\/blood-2002-06-1886"},{"key":"2020021223504623000_REF3","doi-asserted-by":"crossref","unstructured":"Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of fVIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human\/porcine fVIII molecules. Blood.2000;15; 95:564-568.","DOI":"10.1182\/blood.V95.2.564"},{"key":"2020021223504623000_REF4","doi-asserted-by":"crossref","unstructured":"Ananyeva NM, Lacroix-Desmazes S, Hauser CA, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis.2004;15: 109-124.","DOI":"10.1097\/00001721-200403000-00001"},{"key":"2020021223504623000_REF5","doi-asserted-by":"crossref","unstructured":"Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood.2000;95: 1324-1329.","DOI":"10.1182\/blood.V95.4.1324.004k25_1324_1329"},{"key":"2020021223504623000_REF6","doi-asserted-by":"crossref","unstructured":"Qian J, Burkly LC, Smith EP, et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-fVIII inhibitor titer. Eur J Immunol.2000;30: 2548-2554.","DOI":"10.1002\/1521-4141(200009)30:9<2548::AID-IMMU2548>3.0.CO;2-H"},{"key":"2020021223504623000_REF7","doi-asserted-by":"crossref","unstructured":"Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood.2001;97: 2750-2757.","DOI":"10.1182\/blood.V97.9.2750"},{"key":"2020021223504623000_REF8","doi-asserted-by":"crossref","unstructured":"Zambidis ET, Kurup A, Scott DW. Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol Med.1997;3: 212-224.","DOI":"10.1007\/BF03401674"},{"key":"2020021223504623000_REF9","doi-asserted-by":"crossref","unstructured":"Kang Y, Melo MEF, Scott DW. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci U S A.1999;96: 8609-8614.","DOI":"10.1073\/pnas.96.15.8609"},{"key":"2020021223504623000_REF10","doi-asserted-by":"crossref","unstructured":"Gilbert KM, Weigle WO. Tolerogenicity of resting and activated B cells. J Exp Med.1994;179: 249-258.","DOI":"10.1084\/jem.179.1.249"},{"key":"2020021223504623000_REF11","doi-asserted-by":"crossref","unstructured":"Fuchs E, Matzinger P. B cell turn off virgin but not memory T cells. Science.1992;258: 1156-1159.","DOI":"10.1126\/science.1439825"},{"key":"2020021223504623000_REF12","doi-asserted-by":"crossref","unstructured":"Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med.1992;175: 131-138.","DOI":"10.1084\/jem.175.1.131"},{"key":"2020021223504623000_REF13","doi-asserted-by":"crossref","unstructured":"Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest.2000;106: 245-252.","DOI":"10.1172\/JCI9168"},{"key":"2020021223504623000_REF14","doi-asserted-by":"crossref","unstructured":"Melo M, Qian J, El-Amine M, et al. Gene transfer of immunoglobulin-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol2002;168: 4788-4795.","DOI":"10.4049\/jimmunol.168.9.4788"},{"key":"2020021223504623000_REF15","doi-asserted-by":"crossref","unstructured":"Xu B, Scott DW. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol.2004;111: 47-52.","DOI":"10.1016\/j.clim.2003.12.013"},{"key":"2020021223504623000_REF16","doi-asserted-by":"crossref","unstructured":"Song L, Wang J, Wang R, et al. B-cell delivery of GAD-Ig fusion construct induces specific tolerance and prevents diabetes in NOD mice: role of CD4 regulatory cells and TGF-\u03b2. Gene Therapy.2004;11: 1487-1496.","DOI":"10.1038\/sj.gt.3302327"},{"key":"2020021223504623000_REF17","doi-asserted-by":"crossref","unstructured":"Pratt KP, Qian J, Ellaban E, et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost.2004;92: 522-528.","DOI":"10.1160\/TH03-12-0755"},{"key":"2020021223504623000_REF18","doi-asserted-by":"crossref","unstructured":"Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipids biding property of the C2 domain of human factor VIII. Thromb Haemost.2003;89: 788-794.","DOI":"10.1055\/s-0037-1613463"},{"key":"2020021223504623000_REF19","doi-asserted-by":"crossref","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet.1995;10: 119-121.","DOI":"10.1038\/ng0595-119"},{"key":"2020021223504623000_REF20","doi-asserted-by":"crossref","unstructured":"Sarafanov A, Saenko E. High-throughput optimization of protein expression in the baculovirus system based on determination of relative expression efficiency of viral stocks. Anal Biochem.2004;328: 98-100.","DOI":"10.1016\/j.ab.2003.11.028"},{"key":"2020021223504623000_REF21","unstructured":"Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors [abstract]. Thromb Diath Haemorrh. 1975;34: 612."},{"key":"2020021223504623000_REF22","doi-asserted-by":"crossref","unstructured":"Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. Low molecular weight peptides restore the procoagulant activity of fVIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem.2002;277: 27232-27239.","DOI":"10.1074\/jbc.M203415200"},{"key":"2020021223504623000_REF23","doi-asserted-by":"crossref","unstructured":"Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P. Reduction of the inhibitory antibody response to human fVIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood.2004;104: 704-710.","DOI":"10.1182\/blood-2003-11-3891"},{"key":"2020021223504623000_REF24","doi-asserted-by":"crossref","unstructured":"El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol.2000;165: 5631-5636.","DOI":"10.4049\/jimmunol.165.10.5631"},{"key":"2020021223504623000_REF25","doi-asserted-by":"crossref","unstructured":"Lohr J, Knoechel B, Kahn EC, Abbas AK. Role of B7 in T cell tolerance. J Immunol.2004;173: 5028-5035.","DOI":"10.4049\/jimmunol.173.8.5028"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/12\/4865\/1710634\/zh801205004865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/12\/4865\/1710634\/zh801205004865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:51:00Z","timestamp":1581551460000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/12\/4865\/19707\/Induction-of-tolerance-to-factor-VIII-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,15]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-11-4274","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,15]]}}}